Stifel analyst Paul Matteis lowered his price target for Alkermes to $34 from $40 citing the company's increased fiscal 2019 operating expenditure guidance as well as more conservative margin expansion assumptions. Alkermes reported strong Q4 earnings, boosted by several onetime items, contained spending, and strong Aristada sales growth, Matteis tells investors in a post-earnings research note. However, Vivitrol's "so-so" performance and guidance below consensus is a concern, and may remain a "bit of a stock overhang near term," adds the analyst. He keeps a Hold rating on Alkermes.